1. Characteristics of patients in primary and validation cohort.
| Characteristics | Primary cohort | Validation cohort | |||||
| HER2-negative (n=117) | HER2-positive (n=60) | P | HER2-negative (n=105) | HER2-positive (n=57) | P | ||
| HER2, human epidermal growth factor receptor 2; HRad-score, handcrafted radiomics score; DRad-score, deep radiomics score; IQR, interquartile range; P value is calculated from the univariable association analyses between each of the clinicopathological variables and HER2 status. | |||||||
Age (
 ) (year)
|
50.63±9.98 | 50.33±11.48 | 0.864 | 52.64±9.17 | 50.47±7.68 | 0.113 | |
| Tumor location (%) | 0.065 | 0.883 | |||||
| Upper inner quadrant | 42 (23.7) | 14 (7.9) | 31 (19.1) | 20 (12.3) | |||
| Lower inner quadrant | 6 (3.4) | 9 (5.1) | 12 (7.4) | 7 (4.3) | |||
| Lower outer quadrant | 14 (7.9) | 10 (5.6) | 21 (13.0) | 10 (6.2) | |||
| Upper outer quadrant | 55 (31.1) | 27 (15.3) | 41 (25.3) | 20 (12.3) | |||
| HRad-score, median (IQR) | −1.035
(−1.375, −0.590) |
−0.322
(−0.791, 0.095) |
<0.001 | −1.083
(−1.500, −0.581) |
−0.541
(−0.936, 0.0418) |
<0.001 | |
| DRad-score, median (IQR) | −1.012
(−2.041, −0.363) |
−0.143
(−0.691, 0.288) |
<0.001 | −1.308
(−2.056, −0.786) |
−0.278
(−0.777, 0.216) |
<0.001 | |